Aug 27, 2026 04:05PM
Aug 27, 2026 04:05PM
Aug 27, 2026 09:01AM
Aug 18, 2026 03:49PM
Aug 14, 2026 07:15AM
Aug 14, 2026 07:15AM
Aug 12, 2026 09:45PM Outlook Therapeutics prices $55M public offering of stock and warrants
Aug 12, 2026 09:45PM
Aug 12, 2026 04:01PM
Aug 12, 2026 04:01PM
Aug 6, 2026 08:45AM
Jul 27, 2026 06:09AM
Jul 24, 2026 02:40PM
Jul 24, 2026 02:40PM Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Jun 16, 2026 08:02AM
Jun 16, 2026 08:02AM
Jun 1, 2026 08:47AM
Jun 1, 2026 08:46AM
May 28, 2026 04:00PM
May 28, 2026 04:00PM
May 26, 2026 07:03AM Outlook Therapeutics wins FDA appeal for eye drug application
May 26, 2026 07:00AM
May 18, 2026 06:08AM
May 15, 2026 04:05PM
Apr 23, 2026 04:05PM
Apr 23, 2026 04:05PM
Apr 22, 2026 08:30AM
Apr 22, 2026 08:30AM Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Apr 21, 2026 09:05AM
Apr 21, 2026 09:05AM
Apr 7, 2026 08:56AM
Apr 7, 2026 08:50AM
Apr 7, 2026 08:50AM
Mar 25, 2026 04:05PM
Mar 25, 2026 04:05PM Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Mar 24, 2026 07:00AM
Mar 24, 2026 07:00AM
Mar 23, 2026 05:30PM
Mar 23, 2026 05:30PM
Mar 16, 2026 08:06AM
Mar 16, 2026 08:05AM
Mar 5, 2026 04:16PM Outlook Therapeutics meets with FDA on bevacizumab drug approval
Mar 5, 2026 04:15PM
Feb 17, 2026 08:05AM
Feb 11, 2026 08:45AM
Feb 11, 2026 08:45AM
Jan 5, 2026 06:41AM
Jan 2, 2026 07:02AM
Dec 31, 2025 04:15PM Outlook Therapeutics receives FDA rejection for eye drug application
Dec 31, 2025 04:15PM

330,293 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All